Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2009 1
2010 1
2011 4
2012 2
2013 3
2014 4
2015 3
2016 1
2017 5
2018 6
2019 10
2020 9
2021 11
2022 9
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Fizazi K, et al. Among authors: rodriguez antolin a. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578607 Free article. Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Fizazi K, et al. Among authors: rodriguez antolin a. Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12. Lancet Oncol. 2019. PMID: 30987939 Clinical Trial.
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N, Chi KN, Özgüroğlu M, Rodriguez-Antolin A, Feyerabend S, Fein L, Alekseev BY, Sulur G, Protheroe A, Li S, Mundle S, De Porre P, Tran N, Fizazi K. Matsubara N, et al. Among authors: rodriguez antolin a. Eur Urol. 2020 Apr;77(4):494-500. doi: 10.1016/j.eururo.2019.11.021. Epub 2019 Dec 13. Eur Urol. 2020. PMID: 31843335 Clinical Trial.
[Late kidney transplant complications treatment.].
Tejido Sánchez A, Pamplona Casamayor M, Duarte Ojeda JM, Medina Polo J, Miranda Utrera NR, García González L, Arrébola Pajares A, Rodríguez Antolín A. Tejido Sánchez A, et al. Among authors: rodriguez antolin a. Arch Esp Urol. 2021 Dec;74(10):1040-1049. Arch Esp Urol. 2021. PMID: 34851318 Free article. Review. Spanish.
Active surveillance for prostate cancer.
Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV, Touijer KA. Romero-Otero J, et al. Among authors: rodriguez antolin a. Int J Urol. 2016 Mar;23(3):211-8. doi: 10.1111/iju.13016. Epub 2015 Nov 30. Int J Urol. 2016. PMID: 26621054 Free PMC article. Review.
[Benign prostatic hyperplasia management during COVID-19 pandemia.].
Medina-Polo J, Téigell Tobar J, Romero-Otero J, Carballido-Rodríguez J, Domínguez-Esteban M, Martínez-Berganza ML, Miñana-López B, Unda Urzaiz JM, Rodríguez-Antolín A. Medina-Polo J, et al. Among authors: rodriguez antolin a. Arch Esp Urol. 2020 Jun;73(5):405-412. Arch Esp Urol. 2020. PMID: 32538810 Free article. Review. Spanish.
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Carles J, Medina-Lopez RA, Puente J, Gómez-Ferrer Á, Nebra JC, Sáez Medina MI, Ribal MJ, Antolín AR, Álvarez-Ossorio JL, Suárez Novo JF, Agut CM, Srinivasan S, Ortiz J, Fizazi K. Carles J, et al. Among authors: antolin ar. Future Oncol. 2023 Apr;19(12):819-828. doi: 10.2217/fon-2022-1131. Epub 2023 May 24. Future Oncol. 2023. PMID: 37222151 Free article. Clinical Trial.
69 results